PubMed · 6423359
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
F Hanefeld. 1984-04-06. [Muscular dystrophy].. https://pubmed.ncbi.nlm.nih.gov/6423359/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
The purpose of this study was to compare the serological analysis for hepatitis C infection using the recombinant immunoblot assay (RIBA) to the direct in situ localization of the hepatitis C viral genome using the reverse transcriptase (RT) in situ PCR technique. Concurrent sera and liver biopsies from 42 patients with clinical and histologic evidence of chronic liver disease were studied. Antibodies against hepatitis C specific antigens were demonstrated by RIBA in the sera of 39/42 (92%), and PCR amplified viral cDNA was detected in the biopsies of 21 (54%) of the 39 seropositive patients. The detection rate using standard in situ hybridization for the tissues known to be viral positive with RT in situ PCR was 9/21 (42%). It is concluded that approximately one-half of patients with chronic hepatitis and serologic evidence of hepatitis C infection will not have virus detectable in their liver biopsy even with a highly sensitive PCR-based technique.
Although the exact mechanisms inducing the hepatic injury in chronic hepatitis C infection are still not completely elucidated, the evidence of a direct cytopathic viral effect is sparse. The overall majority of experimental studies and clinical observations among patients instead favour immune-mediated hepatocellular damage. This does not exclude the possibility of direct cytopathic viral effects partly contributing to the cell injury. The immune reaction is not always harmful, however. Instead, an intact immune system is probably important for virus clearance in acute infection and after interferon treatment. The therapeutic possibilities are still not adequate, and attempts to understand the immunologic events and manipulate them could perhaps in the future give us more effective tools in the management of this disease.